甲基纳曲酮，一种用于预防和治疗阿片类药物引起的脑外副作用的新型外周μ受体拮抗剂。

Methylnaltrexone, a new peripheral mu-receptor antagonist for the prevention and treatment of opioid-induced extracerebral side effects.

作者信息

Reichle Florian M, Conzen Peter F

机构信息

Ludwig-Maximilians-University, Department of Anesthesiology and Intensive Care Medicine, Nussbaumstrasse 20, 80336, Munich, Germany.

出版信息

Curr Opin Investig Drugs. 2008 Jan;9(1):90-100.

PMID:18183536

Abstract

Progenics Pharmaceuticals Inc and Wyeth Pharmaceuticals are developing methylnaltrexone, a micro-receptor opioid antagonist derived from naltrexone by the addition of a methyl group. The intravenous formulation of methylnaltrexone is currently in phase III clinical trials for the potential treatment of postoperative ileus.

摘要

普洛真科制药公司和惠氏制药公司正在研发甲基纳曲酮，这是一种通过添加甲基从纳曲酮衍生而来的微受体阿片类拮抗剂。甲基纳曲酮的静脉制剂目前正处于治疗术后肠梗阻的III期临床试验阶段。